Send E-mail
  • Boehringer Ingelheim terminates contract with Hanmi Pharma
    Boehringer Ingelheim terminates contract with Hanmi Pharma
     Hanmi Pharmaceutical (128940) said on Sept. 30 that the contract regarding its lung cancer treatment HM61713 with German pharmaceutical firm, Boehringer Ingelheim has been terminated.The German company will be returning its license obtained in 2015, but Hanmi Pharma is not obligated to refund the contract fee worth US$65 million.(theinvestor@heraldcorp.com)
From
Send to
Close Send

Boehringer Ingelheim terminates contract with Hanmi Pharma

Sept. 30, 2016 - 10:44 By 정민경
[DISCLOSURE] Hanmi Pharmaceutical (128940) said on Sept. 30 that the contract regarding its lung cancer treatment HM61713 with German pharmaceutical firm, Boehringer Ingelheim has been terminated.

The German company will be returning its license obtained in 2015, but Hanmi Pharma is not obligated to refund the contract fee worth US$65 million.

(theinvestor@heraldcorp.com)
Most Popular